A Phase 1/2 Study of bbT369, a Dual Targeting CAR T Cell Drug Product With a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Latest Information Update: 05 Feb 2025
Price :
$35 *
At a glance
- Drugs BbT 369 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors 2seventy bio; Regeneron Pharmaceuticals
- 03 Feb 2025 Planned End Date changed from 1 Aug 2025 to 31 Aug 2025.
- 03 Feb 2025 Planned primary completion date changed from 1 Aug 2024 to 31 Aug 2025.
- 03 Feb 2025 Status changed from recruiting to active, no longer recruiting.